Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, 6-week, Double-blind, Randomized, Placebo-controlled, Parallel-design Study to Assess the Efficacy and Safety of NFC-1 in Adolescents (Ages 12-17) With Genetic Disorders Impacting Metabotropic Glutamate Receptors and ADHD

Next Previous
Trial Profile

A Multicenter, 6-week, Double-blind, Randomized, Placebo-controlled, Parallel-design Study to Assess the Efficacy and Safety of NFC-1 in Adolescents (Ages 12-17) With Genetic Disorders Impacting Metabotropic Glutamate Receptors and ADHD

Status: Completed
Phase of Trial: Phase II/III

Latest Information Update: 19 May 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fasoracetam (Primary)
  • Indications Attention-deficit hyperactivity disorder
  • Focus Therapeutic Use
  • Acronyms SAGA
  • Sponsors Aevi Genomic Medicine

Most Recent Events

  • 20 Apr 2017 Updated responder data from a subset of genomically identified patients, published in an Aevi Genomic Medicine media release.
  • 12 Apr 2017 According to an Aevi Genomic Medicine media release, results identifying a genomic subset of responders from the SAGA trial of AEVI-001 will be presented at the 6th World Congress on ADHD (Attention Deficit Hyperactivity Disorder).
  • 20 Mar 2017 According to an Aevi Genomic Medicine media release, Robert L. Findling is a Principal Investigator of this trial.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top